Potassium, an essential dietary mineral that counterbalances sodium, is raised through food, potassium-enriched salt substitutes or supplements for heart and blood vessel health. Evidence is strongest for lower blood pressure, particularly with high blood pressure, and fewer strokes and heart attacks when older, high-risk adults replace salt with the substitute; potassium citrate reduces repeat kidney stones. The main risk is excess blood potassium with reduced kidney function or potassium-retaining medicines. (Full Review)

Protocol

Food-first approach

4,700 mg/day from whole foods

Sodium-to-potassium ratio below one; potatoes, beans, leafy greens, squash, avocado, yogurt, fish. World Health Organization: at least 3,510 mg/day

Salt-substitute approach

All table salt replaced

25% potassium chloride, 75% sodium chloride blend

Supplement approach

780–1,560 mg (20–40 mmol) daily

Prescription chloride or citrate for documented deficiency, diuretic use or kidney stones; usually split into 2–3 doses of no more than 780 mg each

Time to effect

Stroke & cardiovascular events

Several years

Emerged in salt-substitute trials

Blood pressure

2–4 weeks

Fades within weeks of returning to a low-potassium diet

Kidney stone prevention

6–12 months

Potassium citrate in stone formers

Benefits

High: Lower blood pressure, fewer strokes and cardiovascular events, kidney stone prevention

Medium: Lower all-cause mortality, fewer arrhythmias in high-risk heart patients

Low: Bone density preservation, slower kidney function decline, improved glucose metabolism, better endothelial function, muscle preservation in older adults

Speculative: Less arterial calcification

Contraindications

Advanced CKD (chronic kidney disease) with eGFR (a kidney-filtering measure) below 30 mL/min/1.73 m², or below 45 without specialist monitoring

Blood potassium above 5.0 mmol/L at baseline

Users of MRAs (aldosterone-blocking drugs; spironolactone, eplerenone, finerenone) or potassium-sparing diuretics (amiloride, triamterene), unless prescribed by the treating physician

Adrenal insufficiency (Addison's disease) or type 4 renal tubular acidosis (low-aldosterone kidney acid disorder)

Acute kidney injury, severe dehydration, or ongoing vomiting and diarrhea

Heart failure (New York Heart Association Class III–IV, marked symptom limitation) on combined RAAS blockers (drugs acting on the hormone chain controlling salt and blood pressure), without monitoring

Hyperkalemic periodic paralysis (inherited attacks of muscle weakness)

Esophageal stricture (narrowed esophagus), gastric outlet obstruction (blocked stomach emptying) or slowed gut transit (solid potassium chloride tablets)

Anticholinergic drugs (glycopyrrolate, oxybutynin; drugs that slow gut movement): Contraindicated with solid potassium chloride

Key Interactions

ACE inhibitors and ARBs (angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, blood pressure drugs; lisinopril, losartan): Caution; raised hyperkalemia (high blood potassium) risk

Trimethoprim, heparin and calcineurin inhibitors (tacrolimus, cyclosporine; transplant immunosuppressants): Caution; hyperkalemia

NSAIDs (nonsteroidal anti-inflammatory drugs such as ibuprofen, naproxen), over the counter: Caution; raised hyperkalemia risk, especially with ACE inhibitors or ARBs

Licorice (glycyrrhizin): Caution; drains potassium, mainly with regular intake

Loop and thiazide diuretics (strong and moderate fluid-removing drugs; furosemide, hydrochlorothiazide): Monitor; hypokalemia (low blood potassium)

Digoxin (a heart-rhythm drug): Monitor; stable potassium is the goal

Salt substitutes and "lite" salts (NoSalt, LoSalt, Morton Lite Salt), over the counter: Monitor; additive potassium load, particularly with RAAS blockers

Potassium-containing supplements (electrolyte powders, coconut water, multiminerals): Monitor; additive intake

Additive blood-pressure-lowering supplements (magnesium, beetroot nitrate, hibiscus, garlic): Monitor; excess lowering

Magnesium deficiency: Monitor; low potassium resists correction

Prolonged fasting, endurance events and heavy sweating: Monitor; hypokalemia

Risk & Side Effects

High: Hyperkalemia in people with impaired potassium excretion, gastrointestinal irritation and mucosal injury

Low: Blood pressure rise at very high supplemental doses, lower blood bicarbonate with potassium chloride in CKD

Speculative: Calcium phosphate stones with alkali salts

Monitoring

Marker	Target	Why
Blood (serum) potassium	4.2–4.8 mmol/L	Safety and adequacy
eGFR	Above 90 mL/min/1.73 m², stable	Kidney clearance capacity
24-hour urinary potassium	90–120 mmol/day (about 3,500–4,700 mg)	True intake
Urinary sodium-to-potassium ratio (molar)	Below 1.0	Diet balance
Home blood pressure	Below 120/80 mmHg	Primary benefit
Serum bicarbonate	24–28 mmol/L	Acid-base status
Serum magnesium	2.0–2.4 mg/dL	Potassium retention
24-hour urinary citrate and urine pH (stone formers)	No established functional target; rise from own baseline, citrate above 320 mg/day, pH 6.0–6.5	Stone prevention

Cadence: Baseline before raising intake beyond food; 1–2 weeks after starting supplements or a salt substitute (eGFR below 60 or on RAAS blockers), again at 3 months, then every 6–12 months while intake stays stable. Home blood pressure 7-day average at baseline, 4 weeks and quarterly; stone formers add urinary citrate and urine pH at 3–6 months.

Qualitative Assessment

Fewer muscle cramps, including at night
Steadier energy and absence of unusual fatigue
No palpitations, skipped beats or new muscle weakness (possible hyperkalemia)
No heartburn, abdominal pain or dark stools (possible gut irritation)
Fewer blood pressure–related headaches or lightheadedness

Potassium for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment